Recent advances in immuno-oncology have increased understanding of the tumor immune microenvironment (TIME), and clinical trials for immune checkpoint inhibitor treatment have shown remission and/or durable response in certain proportions of patients stratified by predictive biomarkers. The TIME in colorectal cancer (CRC) was initially evaluated several decades ago. The prognostic value of the immune response to tumors, including tumor-infiltrating lymphocytes, peritumoral lymphoid reaction, and Crohn’s-like lymphoid reaction, has been well demonstrated. In this review, we describe the chronology of TIME research and review the up-to-date high-dimensional TIME landscape of CRC. We also summarize the clinical relevance of several biomarkers associated with immunotherapy in CRC, such as microsatellite instability, tumor mutational burden, POLE/POLD mutation, consensus molecular subtype, and programmed death-ligand 1 expression.
Citations
Citations to this article as recorded by
Targeting the “tumor microenvironment”: RNA-binding proteins in the spotlight in colorectal cancer therapy Yiwei Zhang, Yujun Zhang, Jingjing Song, Xifu Cheng, Chulin Zhou, Shuo Huang, Wentao Zhao, Zhen Zong, Lingling Yang International Immunopharmacology.2024; 131: 111876. CrossRef
Five decades of colorectal cancer pathology: The World and China Maode Lai Chinese Science Bulletin.2024;[Epub] CrossRef
T cell receptor clonotype in tumor microenvironment contributes to intratumoral signaling network in patients with colorectal cancer In Hye Song, Seung-been Lee, Byung-Kwan Jeong, Jungwook Park, Honggeun Kim, GunHee Lee, Su Min Cha, Heejae Lee, Gyungyub Gong, Nak-Jung Kwon, Hee Jin Lee Immunologic Research.2024; 72(5): 921. CrossRef
Identification of Key Immune and Cell Cycle Modules and Prognostic Genes for Glioma Patients through Transcriptome Analysis Kaimin Guo, Jinna Yang, Ruonan Jiang, Xiaxia Ren, Peng Liu, Wenjia Wang, Shuiping Zhou, Xiaoguang Wang, Li Ma, Yunhui Hu Pharmaceuticals.2024; 17(10): 1295. CrossRef
Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study Ippokratis Messaritakis, Eleni Psaroudaki, Konstantinos Vogiatzoglou, Maria Sfakianaki, Pantelis Topalis, Ioannis Iliopoulos, Dimitrios Mavroudis, John Tsiaoussis, Nikolaos Gouvas, Maria Tzardi, John Souglakos Cancers.2023; 15(19): 4819. CrossRef
Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer Moonsik Kim, Ji Yun Jeong, An Na Seo Diagnostics.2023; 13(17): 2782. CrossRef
Evaluation on Braking Stability of Autonomous Vehicles Running along Curved Sections Based on Asphalt Pavement Adhesion Properties Binshuang Zheng, Xiaoming Huang, Junyao Tang, Jiaying Chen, Runmin Zhao, Zhengqiang Hong, Tao Tang, Meiling Han, Yang Yang Journal of Advanced Transportation.2022; 2022: 1. CrossRef
Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas Minsun Jung, Ji Ae Lee, Seung-Yeon Yoo, Jeong Mo Bae, Gyeong Hoon Kang, Jung Ho Kim Modern Pathology.2022; 35(12): 2011. CrossRef
Association of Tumor-Infiltrating Lymphocytes With Survival in Stages II and III Colorectal Cancer Marina Vitorino, Inês Eiriz, Tiago C Tomás, Rodrigo Vicente, Ana Mendes, Ana Rita Freitas, Sofia Braga, Catarina Alves-Vale, Paula Borralho, André Ferreira, Luisa Leal da Costa Cureus.2022;[Epub] CrossRef
Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis Yan Li, Yiqi Ma, Zijun Wu, Fanxin Zeng, Bin Song, Yanrong Zhang, Jinxing Li, Su Lui, Min Wu Frontiers in Immunology.2021;[Epub] CrossRef
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers Jung Ho Kim, Mi-Kyoung Seo, Ji Ae Lee, Seung-Yeon Yoo, Hyeon Jeong Oh, Hyundeok Kang, Nam-Yun Cho, Jeong Mo Bae, Gyeong Hoon Kang, Sangwoo Kim Journal for ImmunoTherapy of Cancer.2021; 9(12): e003414. CrossRef